The European First Episode Schizophrenia Trial (EUFEST) was initiated in 2005 as a multicentre open-label trial comparing treatment with amisulpride, quetiapine, olanzapine or ziprasidone to low-dose haloperidol in patients with schizophrenia who had minimal prior exposure to antipsychotics (Fleischhacker et al. Schizophr Res 2005;78:147-156).